Hydroxycarbamide Pharmacenter

Hydroxycarbamide, the active ingredient in Hydroxycarbamide Pharmacenter, is an antineoplastic agent presented as an oral formulation for oral use. It is used to manage sickle cell disease and certain myeloproliferative disorders in adults. GNH USA supplies Hydroxycarbamide Pharmacenter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Hydroxycarbamide is used to treat disorders of abnormal blood cell production and sickling disorders.

- Sickle cell disease: reduces the frequency of painful vaso‑occlusive crises. - Polycythemia vera: controls elevated red blood cell mass and hematocrit. - Essential thrombocythemia: lowers platelet count to reduce thrombotic risk. - Chronic myelogenous leukemia: contributes to disease control as part of combination therapy.

Hydroxycarbamide may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting. - Fatigue or weakness. - Hair thinning or loss. - Skin rash or discoloration. - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Bone‑marrow suppression leading to anemia, neutropenia or thrombocytopenia. - Severe infections due to immunosuppression. - Hepatotoxicity with elevated liver enzymes. - Allergic reactions including angioedema. - Rare cases of secondary malignancies. - Pulmonary toxicity such as interstitial pneumonitis.

Hydroxycarbamide requires careful monitoring and patient selection.

- Blood count monitoring: regular CBC to detect marrow suppression. - Renal function: avoid use in severe renal impairment without dose adjustment. - Pregnancy: safety unknown; use only if benefit outweighs risk. - Concomitant myelosuppressive agents: avoid or adjust therapy. - Hepatic dysfunction: monitor liver enzymes and adjust dose if needed. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Hydroxycarbamide can interact with several medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Allopurinol: may increase hydroxycarbamide toxicity. - Live vaccines: immunosuppression can reduce vaccine efficacy. - Other cytotoxic chemotherapy agents: heightened risk of marrow suppression. - Methotrexate: additive myelosuppressive effect.

Moderate Interactions (Monitor Closely): - NSAIDs: increased risk of gastrointestinal irritation. - Penicillins: possible reduction in hydroxycarbamide efficacy. - Phenytoin: may alter drug metabolism and plasma levels. - Antifungal azoles: may affect hydroxycarbamide clearance. - Anticoagulants: enhanced bleeding risk due to platelet effects.